For the first time, clinical interventions targeting biological aging have produced statistically significant human results — and the timeline for market availability has compressed in ways the longevity field has not yet fully communicated.
AI-designed drug candidates are entering clinical trials, quantum computers are outperforming classical systems on specific problems, and protein structure prediction has solved challenges that occupied structural biologists for decades. The transformation of the scientific method is underway.
After a decade of overhyped promises, microbiome science is producing reproducible clinical results in specific conditions. The interventions that work, and why they work, reveal a biology far stranger and more consequential than the popular science version.
Google's Willow chip and subsequent advances have compressed the timeline for fault-tolerant quantum computing by a decade. The industries that depend on current encryption standards should be treating this as an active risk, not a theoretical one.
Epidemiologists have identified a set of measurable signals that historically precede major zoonotic spillover events. Several of them are currently elevated.
Billions are flowing into research that promises to add decades to the human lifespan. The science is more serious than the hype — and more uncertain than the investors admit.